ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VTGN VistaGen Therapeutics Inc

4.75
0.05 (1.06%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 194,533
Bid Price 4.69
Ask Price 4.84
News -
Day High 4.85

Low
1.62

52 Week Range

High
24.71

Day Low 4.65
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 1.06% 4.75 17:14:08
Open Price Low Price High Price Close Price Prev Close
4.71 4.65 4.85 4.75 4.70
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,388 194,533 $ 4.75 $ 923,388 - 1.62 - 24.71
Last Trade Time Type Quantity Stock Price Currency
16:00:06 formt 108 $ 4.75 USD

VistaGen Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
128.64M 27.03M - -227k -59.25M -2.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VTGN Message Board. Create One! See More Posts on VTGN Message Board See More Message Board Posts

Historical VTGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.685.004.554.76160,6850.071.50%
1 Month5.405.744.535.09243,260-0.65-12.04%
3 Months4.775.743.91144.86261,053-0.02-0.42%
6 Months3.095.862.45014.45404,3061.6653.72%
1 Year4.13724.711.626.121,213,3310.61314.82%
3 Years63.00106.501.6216.713,378,912-58.25-92.46%
5 Years31.50106.501.6221.792,544,602-26.75-84.92%

VistaGen Therapeutics Description

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Your Recent History

Delayed Upgrade Clock